COVID-19 and comorbidities: a systematic review and meta-analysis
Top Cited Papers
- 14 July 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Postgraduate Medicine
- Vol. 132 (8), 749-755
- https://doi.org/10.1080/00325481.2020.1786964
Abstract
SARS-CoV-2 has caused a worldwide pandemic that began with an outbreak of pneumonia cases in the Hubei province of China. Knowledge of those most at risk is integral for treatment, guideline implementation, and resource allocation. We conducted a systematic review and meta-analysis to evaluate comorbidities associated with severe and fatal cases of COVID-19. A search was conducted on PubMed and EmBase on 20 April 2020. Pooled estimates were collected using a random-effects model. Thirty-three studies were included in the systematic review and twenty-two in the meta-analysis. Of the total cases 40.80% (95%CI: 35.49%, 46.11%) had comorbidities, while fatal cases had 74.37% (95%CI: 55.78%, 86.97%). Hypertension was more prevalent in severe [47.65% (95%CI: 35.04%, 60.26%)] and fatal [47.90% (95%CI: 40.33%, 55.48%)] cases compared to total cases [14.34% (95%CI: 6.60%, 28.42%)]. Diabetes was more prevalent among fatal cases [24.89% (95%CI: 18.80%, 32.16%)] compared to total cases [9.65% (95%CI: 6.83%, 13.48%)]. Respiratory diseases had a higher prevalence in fatal cases [10.89% (95%CI: 7.57%, 15.43%)] in comparison to total cases [3.65% (95%CI: 2.16%, 6.1%)]. Studies assessing the mechanisms accounting for the associations between severe cases and hypertension, diabetes, and respiratory diseases are crucial in understanding this new disease, managing patients at risk, and developing policies and guidelines that will reduce future risk of severe COVID-19 disease.Keywords
This publication has 49 references indexed in Scilit:
- Systems Medicine as an Emerging Tool for Cardiovascular GeneticsFrontiers in Cardiovascular Medicine, 2016
- Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infectionsNature Communications, 2014
- Immunosenescent CD8 + T Cells and C-X-C Chemokine Receptor Type 3 Chemokines Are Increased in Human HypertensionHypertension, 2013
- Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and DiseaseInternational Journal of Peptides, 2012
- The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in DiabetesPPAR Research, 2012
- Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- Effect of Statin Therapy on C-Reactive Protein LevelsJAMA, 2001
- Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary HypercholesterolemiaCirculation, 2001
- Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive ProteinCirculation, 1999